OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	60
CAR T-cell therapy comes of age: Introductory editorial for the special issue	55
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	52
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	45
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	43
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	43
How to set up a clinical research center in Brazil, as an example of a middle-income country	43
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	40
Epidemiology and etiology of diffuse large B-cell lymphoma	36
TET2 mutation as prototypic clonal hematopoiesis lesion	34
Somatic mutations in “benign” blood diseases	34
Lessons learned from the Eµ-TCL1 mouse model of CLL	32
The role of viruses in HIV-associated lymphomas	27
Antibody and immunotherapy in diffuse large B-cell lymphoma	26
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	25
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	24
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	22
Vaccinations in patients with chronic lymphocytic leukemia	21
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	18
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's macroglobulinemia on the Management of Patients with Intolerance or Resistance to covalent BTK inhibitors	16
The molecular map of CLL and Richter's syndrome	16
outside front cover, PMS 8883 metallic AND 4/C	15
outside front cover, PMS 8883 metallic AND 4/C	15
Tribute to an editor: Neal S. Young As a Medical Editor and Writer	14
Clonal hematopoiesis	14

Cellular and immunotherapies for myelodysplastic syndromes	13
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	13
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	13
The biology of classical Hodgkin lymphoma	12
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	11
outside front cover, PMS 8883 metallic AND 4/C	11
Mendelian inheritance of anemia due to disturbed iron homeostasis	10
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	9
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	9
Challenges and opportunities of CAR T-cell therapies for CLL	9
Aplastic anemia: Quo vadis?	9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	8
The pediatric approach to Hodgkin lymphoma	8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	8
Genetics of somatic auto-inflammatory disorders	8
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	8
Understanding MDS stem cells: Advances and limitations	7
VEXAS within the spectrum of rheumatologic disease	7
Somatic compensation of inherited bone marrow failure	7
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	7
Somatic mutations in acquired pure red cell aplasia	7
Iron and erythropoiesis: A mutual alliance	7
Clinical applications of circulating tumor DNA in central nervous system lymphoma	6
DLBCL arising from indolent lymphomas: How are they different?	6
The crossroads of cancer therapies and clonal hematopoiesis	6
REPORT OF CONSENSUS PANEL 2 FROM THE 12TH INTERNATIONAL WORKSHOP ON THE MANAGEMENT OF BING-NEEL SYNDROME IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA.	5
outside front cover, PMS 8883 metallic AND 4/C	5
miRNA Biology in Chronic Lymphocytic Leukemia	5
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	5
20 years of Hepcidin: How far we have come	5
Measurable residual disease after CAR T-cell therapy	5
License for a CAR T: Examining patient eligibility	5
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	5
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	5
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	5
Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the Management of Patients with High-Risk Disease.	5
outside front cover, PMS 8883 metallic AND 4/C	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	4
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	4
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	4
Inflammation in myelodysplastic syndrome pathogenesis	4
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	4
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	4
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	4
RNA splicing as a therapeutic target in myelodysplastic syndromes	4
outside front cover, PMS 8883 metallic AND 4/C	4
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	4
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	4
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4

Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	4
Platelet-activating anti-PF4 disorders: An overview	3
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	3
Role of the tumor microenvironment in CLL pathogenesis	3
Toward a pathophysiology inspired treatment of VEXAS syndrome	3
Shaping the bone through iron and iron-related proteins	3
Special edition of the Seminars in Hematology series on Global Hematology Care	3
The case for prioritizing malignant hematology services in low- and middle-income countries	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
outside front cover, PMS 8883 metallic AND 4/C	3
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	3
Tuning CAR T-cell therapies for efficacy and reduced toxicity	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	2
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	2
outside front cover, PMS 8883 metallic AND 4/C	2
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	2
Cell-free DNA in large B-cell lymphoma: MRD and beyond	2
masthead	2
Immunosuppressive therapy in severe aplastic anemia	2
Special issue on circulating tumor DNA: Introductory editorial	2
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	2
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	2
Smoldering multiple myeloma: Integrating biology and risk into management	2
The Management of older patients with Hodgkin lymphoma: implications of S1826	2
Applications of virus-specific T cell therapies post-BMT	2
Beyond HMAs: Novel Targets and Therapeutic Approaches	2
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	2
outside front cover, PMS 8883 metallic AND 4/C	2
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	2